Predicting the impact of new pneumococcal conjugate vaccines: Serotype composition is not enough

Expert Review of Vaccines

Volumn 14, Issue 3, 2015, Pages 413-428

  Hausdorff, William P ^a   Hoet, Bernard ^a   Adegbola, Richard A ^a  

^a GSK   (Belgium)

Author keywords

acute otitis media; cross protection; cross reactivity; herd protection; higher valent vaccines; invasive pneumococcal disease; nasopharyngeal carriage; pneumococcal conjugate vaccines; pneumococcus; pneumonia; serotype replacement

Indexed keywords

PLACEBO; PNEUMOCOCCUS VACCINE; BACTERIAL ANTIGEN; VACCINE;

ACUTE OTITIS MEDIA; ANTIBODY RESPONSE; CROSS PROTECTION; CROSS REACTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; HERD IMMUNITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NASOPHARYNX; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION; COMPARATIVE STUDY; HETEROZYGOTE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PREVENTION AND CONTROL; STREPTOCOCCAL INFECTIONS;

ANTIGENS, BACTERIAL; CARRIER STATE; CROSS PROTECTION; CROSS REACTIONS; HUMANS; IMMUNITY, HERD; PNEUMOCOCCAL VACCINES; SEROGROUP; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 84923115954     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.965160     Document Type: Review

References (111)

1. Klugman KP, Cutts F, Adegbola RA, et al. Meta-analysis of the efficacy of conjugate vaccines against invasive pneumococcal disease. In: Siber GR, Klugman KP, Mäkelä PH, editors. Pneumococcal vaccines: the impact of conjugate vaccine. ASM Press; Washington, DC, USA: 2008
2. Taylor S, Marchisio P, Vergison A, et al. Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clin Infect Dis 2012;54(12): 1765-73
3. Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2012;31(5): 501-8
4. Feikin DR, Kagucia EW, Loo JD, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med 2013;10(9):e1001517
5. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201(1): 32-41
6. Pneumococcal vaccines WHO position paper-. 2012. Wkly Epidemiol Rec 2012; 87(14):129-44
7. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000;30(1): 100-21
8. Wroe PC, Lee GM, Finkelstein JA, et al. Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J 2012;31(3):249-54
9. Hausdorff WP, Fierens F, Hoet B. Efficacy and effectiveness of PHiD-CV against invasive pneumococcal disease and pneumonia: recent data. Presented at Nordic Vaccine Meeting; 5-7 September 2012; Copenhagen, Denmark
10. Andrews N, Waight PA, Borrow R, et al. Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales. PLoS One 2011;6(12):e28435
11. Palmu AA, Jokinen J, Nieminen H, et al. Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial. Lancet Resp Med 2014;doi; 10.1016/S2213-2600 (14)70139-0. [Epub ahead of print]
12. Lee H, Choi EH, Lee HJ. Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines. Korean J Pediatr 2014;57(2):55-66
13. Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002;21(9): 810-15
14. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344(6):403-9
15. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006;368(9546): 1495-502
16. Bettinger JA, Scheifele DW, Kellner JD, et al. The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine 2010;28(9):2130-6
17. Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010;28(25):4192-203
18. Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009; 28(4 Suppl):S66-76
19. Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011;11(10):760-8
20. De Wals P, Lefebvre B, Markowski F, et al. Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine 2014;32(13):1501-6
21. Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis 2014;14(9):839-46
22. Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005; 365(9465):1139-46
23. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003;349(14):1341-8
24. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005;5(2):83-93
25. Yaro S, Lourd M, Traore Y, et al. Epidemiological and molecular characteristics of a highly lethal pneumococcal meningitis epidemic in Burkina Faso. Clin Infect Dis 2006;43(6): 693-700
26. Lipsitch M, Whitney CG, Zell E, et al. Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease? PLoS Med 2005; 2(1):e15
27. Heffron R. Pneumonia: with special reference to Pneumococcus lobar pneumonia. Commonwealth Fund; Cambridge, London, UK: 1939
28. Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993;270(15): 1826-31
29. Singleton RJ, Butler JC, Bulkow LR, et al. Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults. Vaccine 2007;25(12):2288-95
30. Klugman KP, Madhi SA, Adegbola RA, et al. Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose. Vaccine 2011;29(18):3372-3
31. Miller E, Andrews NJ, Waight PA, et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011;29(49):9127-31
32. Andrews NJ, Waight PA, George RC, et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012; 30(48):6802-8
33. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006; 367(9512):740-8
34. Puumalainen T, Dagan R, Wuorimaa T, et al. Greater antibody responses to an eleven valent mixed carrier diphtheria-or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants. Pediatr Infect Dis J 2003;22(2):141-9
35. Togashi T, Yamaji M, Thompson A, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan. Pediatr Infect Dis J 2013; 32(9):984-9
36. Poolman J, Kriz P, Feron C, et al. Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics. Vaccine 2009;27(24):3213-22
37. Dagan R, Patterson S, Juergens C, et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis 2013; 57(7):952-62
38. Steens A, Bergsaker MA, Aaberge IS, et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 2013;31(52):6232-8
39. Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 2014. doi: 10.1093/cid/ciu524. [Epub ahead of print]
40. Demczuk WH, Martin I, Griffith A, et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Can J Microbiol 2013;59(12): 778-88
41. JCVI pneumococcal sub-committee meeting. Available from: http://media.dh. gov.uk/network/261/files/2012/07/JCVI-minutes-Pneumococcal-sub-committee-meeting-held-on-30-May-2012.pdf [Last accessed 7 March 2014]
42. Millar EV, O'Brien KL, Bronsdon MA, et al. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine. Clin Infect Dis 2007; 44(9):1173-9
43. Tregnaghi MW, Saez-Llorens X, Lopez P, et al. for the COMPAS Group. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med 2014;11(6): e1001657
44. Kilpi T, Ahman H, Jokinen J, et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis 2003;37(9):1155-64
45. Jokinen JT, Ahman H, Kilpi TM, et al. Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. J Infect Dis 2004;190(3):545-50
46. De Wals P, Erickson L, Poirier B, et al. How to compare the efficacy of conjugate vaccines to prevent acute otitis media? Vaccine 2009;27(21):2877-83
47. Alpert HR, Behm I, Connolly GN, Kabir Z. Smoke-free households with children and decreasing rates of paediatric clinical encounters for otitis media in the United States. Tob Control 2011;20(3):207-11
48. Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009 (4):CD004977
49. Loo JD, Conklin L, Fleming-Dutra KE, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia. Pediatr Infect Dis J 2014;33(Suppl 2): S140-51
50. Hausdorff WP, Dagan R. Serotypes and pathogens in paediatric pneumonia. Vaccine 2008;26 Suppl 2:B19-23
51. Root ED, Lucero M, Nohynek H, et al. Distance to health services affects local-level vaccine efficacy for pneumococcal conjugate vaccine (PCV) among rural Filipino children. Proc Natl Acad Sci USA 2014; 111(9):3520-5
52. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 1995;33(10):2759-62
53. Robbins JB, Austrian R, Lee CJ, et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983;148(6):1136-59
54. Foster D, Walker AS, Paul J, et al. Reduction in invasive pneumococcal disease following implementation of the conjugate vaccine in the Oxfordshire region, England. J Med Microbiol 2011;60(Pt 1):91-7
55. Park IH, Moore MR, Treanor JJ, et al. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 2008;198(12):1818-22
56. Richter SS, Heilmann KP, Dohrn CL, et al. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011. Emerg Infect Dis 2013; 19(7):1074-83
57. Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007;25(19):3816-26
58. Dagan R, Givon-Lavi N, Porat N, Greenberg D. The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial. Vaccine 2012;30(34): 5132-40
59. O'Brien KL, Millar EV, Zell ER, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis 2007;196(8):1211-20
60. Grivea IN, Tsantouli AG, Michoula AN, Syrogiannopoulos GA. Dynamics of Streptococcus pneumoniae nasopharyngeal carriage with high heptavalent pneumococcal conjugate vaccine coverage in Central Greece. Vaccine 2011;29(48): 8882-7
61. Ho PL, Chiu SS, Chan MY, et al. Changes in nasopharyngeal carriage and serotype distribution of antibiotic-resistant Streptococcus pneumoniae before and after the introduction of 7-valent pneumococcal conjugate vaccine in Hong Kong. Diagn Microbiol Infect Dis 2011;71(4):327-34
62. Ekström N, Haikala R, Lehtonen H, et al. Functional activity of antibodies to pneumococcal serotypes 6A and 19A in the Finnish Otitis Media (FinOM) Vaccine Trial. Presented at 4th International Symposium on Pneumococci and Pneumococcal Diseases; 9-13 May 2004; Helsinki, Finland
63. Wysocki J, Tejedor JC, Grunert D, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J 2009;28(4 Suppl):S77-88
64. SIREVA II. Available from: http://www. paho.org/hq/index.php?option=com- content&view=category&layout= blog&id=3609&Itemid=3953&lang=pt [Last accessed 7 March 2014]
65. McEllistrem MC, Nahm MH. Novel pneumococcal serotypes 6C and 6D: anomaly or harbinger. Clin Infect Dis 2012; 55(10):1379-86
66. Kuch A, Sadowy E, Skoczynska A, Hryniewicz W. First report of Streptococcus pneumoniae serotype 6D isolates from invasive infections. Vaccine 2010;28(39): 6406-7
67. Cooper D, Yu X, Sidhu M, et al. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 2011;29(41): 7207-11
68. Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr 2010;10:4
69. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007;196(9): 1346-54
70. Poolman J, Frasch C, Nurkka A, et al. Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines. Clin Vaccine Immunol 2011;18(2):327-36
71. Mrkvan T, Hoet B, Adegbola RA, et al. Serotype 19A and the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV): lessons learned to date. Presented at 31st Meeting of the European Society for Paediatric Infectious Diseases; 28 May-1 June 2013; Milan, Italy
72. de Wals P, Lefebvre B, Defay F, et al. Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada. Vaccine 2012;30(45):6416-20
73. Kilpi T, Palmu AA, Ruokokoski E, et al. Indirect impact of pneumococcal Haemophilus influenzae protein-D conjugate vaccine (PHID-CV10) on invasive pneumococcal disease (IPD) in a clinical trial. Presented at 8th World Congress on Pediatric Infectious Diseases; 19-22 November 2013; Cape Town, South Africa
74. Invasive pneumococcal disease reports in New Zealand. Available from: https://surv. esr.cri.nz/surveillance/IPD.php [Last accessed 7 March 2014]
75. Impact of 10-valent pneumococcal conjugate vaccine (PCV10) against invasive pneumococcal disease (IPD) among vaccine-eligible children in Finland. Available from: http://www.slideshare.net/THLfi/ip-ddirect-nvpwspid2013finland [Last accessed March7 2014]
76. Quebec: INSPQ Annual surveillance report 2010. Available from: http://www.inspq.qc. ca/pdf/publications/1383-ProgSurvPneumocoque2010.pdf [Last accessed 7 March 2014]
77. Domingues CMAS, Verani JR, Montenegro ER, et al. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study Lancet Resp Med. 2014;in press
78. de Wals P. Invasive pneumococcal disease in two birth cohorts vaccinated, respectively, with 2+1 PCV-7 or PHiD-CV-10 doses. Presented at 8th International Symposium on Pneumococci and Pneumococcal Diseases; 11-15 March 2012; Iguaçu Falls, Brazil
79. Moore M, Taylor T, Pondo T, et al. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease (IPD) among children <5 years old in the U.S. Pneumonia 2014;3:149
80. Simell B, Auranen K, Kayhty H, et al. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines 2012;11(7):841-55
81. Hausdorff WP, Brueggemann AB, Hackell JG, Scott JA. Pneumococcal serotype epidemiology. In: Siber GR, Klugman KP, Mäkelä PH, editors. Pneumococcal Vaccines: the impact of conjugate vaccine. ASM Press; Washington, DC, USA: 2008
82. van den Bergh MR, Spijkerman J, Swinnen KM, et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis 2013;56(3):e30-9
83. Van Effelterre T, Moore MR, Fierens F, et al. A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination. Vaccine 2010;28(21):3650-60
84. Brandileone MCC, Almeida SCG, Zanella RC, et al. Effect of PCV10 vaccination on pneumococcal serotypes in Brazil using the national pneumococcal laboratory network surveillance. Pneumonia 2014;3:158
85. Vesikari T, Forstén A, Seppä I, et al. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage in Finnish children: a cluster-randomised controlled trial. Presented at 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 27-30 April 2013; Berlin, Germany
86. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378(9807):1962-73
87. van Gils EJ, Veenhoven RH, Hak E, et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA 2009;302(2):159-67
88. Cohen R, Levy C, Bonnet E, et al. Dynamic of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 introduction in France. Vaccine 2010;28(37):6114-21
89. Huang SS, Hinrichsen VL, Stevenson AE, et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics 2009;124(1):e1-11
90. Vestrheim DF, Hoiby EA, Aaberge IS, Caugant DA. Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin Vaccine Immunol 2010;17(3):325-34
91. Prymula R, Hanovcova I, Splino M, et al. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. Vaccine 2011;29(10):1959-67
92. Russell FM, Carapetis JR, Satzke C, et al. Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster. Clin Vaccine Immunol 2010; 17(12):1970-6
93. Roca A, Hill PC, Townend J, et al. Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial. PLoS Med 2011; 8(10):e1001107
94. Nzenze SA, Shiri T, Nunes MC, et al. Temporal changes in pneumococcal colonization in a rural African community with high HIV prevalence following routine infant pneumococcal immunization. Pediatr Infect Dis J 2013;32(11):1270-8
95. Yeh SH, Zangwill KM, Lee H, et al. Heptavalent pneumococcal vaccine conjugated to outer membrane protein of Neisseria meningitidis serogroup b and nasopharyngeal carriage of Streptococcus pneumoniae in infants. Vaccine 2003; 21(19-20):2627-31
96. Dagan R, Melamed R, Muallem M, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996;174(6):1271-8
97. Sáez-Llorens X, Wong D, Rodŕiguez M, et al. Effect of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccines (PHiD-CV) on nasopharyngeal bacterial carriage in Panamanian children. Presented at 7th World Congress of the World Society for Pediatric Infectious Diseases; 16-19 November 2011; Melbourne, Australia
98. Weinberger DM, Harboe ZB, Flasche S, et al. Prediction of serotypes causing invasive pneumococcal disease in unvaccinated and vaccinated populations. Epidemiology 2011;22(2):199-207
99. Weinberger DM, Bruden DT, Grant LR, et al. Using pneumococcal carriage data to monitor postvaccination changes in invasive disease. Am J Epidemiol 2013;178(9): 1488-95
100. Nurhonen M, Auranen K. Optimal serotype compositions for Pneumococcal conjugate vaccination under serotype replacement. PLoS Comput Biol 2014;10(2):e1003477
101. Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009;360(3):244-56
102. Cohen AL, Harrison LH, Farley MM, et al. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS 2010;24(14):2253-62
103. Madhi SA, Klugman KP. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004; 10(8):811-13
104. Dunne EM, Smith-Vaughan HC, Robins-Browne RM, et al. Nasopharyngeal microbial interactions in the era of pneumococcal conjugate vaccination. Vaccine 2013;31(19):2333-42
105. Barkai G, Leibovitz E, Givon-Lavi N, Dagan R. Potential contribution by nontypable Haemophilus influenzae in protracted and recurrent acute otitis media. Pediatr Infect Dis J 2009;28(6):466-71
106. Jokinen J, Palmu AA, Kilpi T. Acute otitis media replacement and recurrence in the Finnish otitis media vaccine trial. Clin Infect Dis 2012;55(12):1673-6
107. Borys D, Saez-Llorens X, Prymula R, et al. 10-and 11-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccines (PHiD-CV and 11PN-PD) on nasopharyngeal bacterial carriage. Presented at 8th International Symposium on Pneumococci and Pneumococcal Diseases; 11-15 March 2012; Iguacu Falls, Brazil
108. Deceuninck G, De Wals P. Effectiveness of three pneumococcal conjugate vaccines (PCVs) to prevent invasive pneumococcal disease (IPD) in Quebec, Canada. Pneumonia 2014;3:163
109. Nurkka A, Ahman H, Yaich M, et al. Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT. Vaccine 2002;20(1-2): 194-201
110. Prince Valdemar of Denmark, Wikipedia. Available from: http://en.wikipedia.org/wiki/Prince-Valdemar-of-Denmark
111. Bacterial Meningitis in the Netherlands: annual Reports for 2010 and 2012. Available from: www.amc.nl/web/Research/Departments/Overview/Medical-Microbiology/Medical-Microbiology/Current-research/Reference-Laboratory-for-Bacterial-Meningitis.htm?print=true [Last accessed 7 March 2014]